EN DE
Watch Hangzhou Diagens Biotech Co for free: we tell you when fair value or trend changes.
Data-driven stock valuation

Hangzhou Diagens Biotech Co (2526) fair value: what the stock is really worth

As of Nov 10, 2026: fair value (intrinsic value) of Hangzhou Diagens Biotech Co stock HK$52.88, price HK$94.75, that is 44.2% below the price, quality 58 out of 100. Rating: strongly overvalued. The value is an estimate: none of our valuation models currently carries, it draws on revenue and assets compared with similar companies. Updated daily.

  1. Keep an eye on it?Free in your watchlist: 5 stocks without an account, 10 with one Yes, for free

Healthcare HK · Based in China

HD Hangzhou Diagens Biotech Co logo Thin data Nov 10, 2026

Hangzhou Diagens Biotech Co

2526 · HK
Stretched Valuation

Our calculation puts a fair price 44% below what the stock costs today.

Low debt
Revenue last quarter +21% vs. a year ago.
Quality 58/100
Expensive Growth (revenue YoY +133.7 %/yr in CNY)
Fair value HK$52.88 · Strongly overvalued
Loss-making · -66.4% net margin (TTM)
Negative free cash flow
Trails peers (3/9)
Narrow moat 12/100 · thin data
Thin data
Estimate
Watch Hangzhou Diagens Biotech Co for free: we tell you when fair value or trend changes. Watch for free

What runs behind every stock

26 valuation models 8 families, DCF to NCAV 37 quality factors margins, balance sheet, cashflow, debt 6 AI factors moat, what no ratio measures 2,000+ data points verified, per stock, median

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

HK$723.00 HK$94.75 Fair Value HK$52.88 Mar 2026 Nov 2026

White line = price, green steps = our fair value per fiscal year. As of Nov 10, 2026.

How to read this chart

7‑month range HK$94.75 – HK$723.00 · fair‑value band HK$39.66 – HK$66.10 · the HK$94.75 price screens above the HK$52.88 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). As of Nov 10, 2026.

Follow Hangzhou Diagens Biotech Co in your weekly email

Every Wednesday you see whether Hangzhou Diagens Biotech Co is on track or worth a review, plus price against fair value. Free, up to 3 stocks.

We send you a confirmation link. Unsubscribe with one click.

Which stocks are undervalued right now? Check free Discover now →

Company profile

Hangzhou Diagens Biotechnology Co., Ltd., a medical devices company, develops medical imaging products and services. It operates through Medical Imaging Software and Medical Devices, Technology Licensing, Analysis and Consulting Services, and Others segments.

Show moreShow less

The company's products portfolio include AI AutoVision, a chromosome karyotype assisted diagnosis and analysis system that provides intelligent karyotyping analysis with applications across genetics and hematologic oncology; MetaSight automatic cell microscopic image scanning system, which enables automated scanning, positioning, image acquisition, and output of chromosome or cell samples for a range of cytogenetics applications, including genetics health, radiation health, and hemato-oncology; and KayoFlow automatic cell harvester for pre-analytical processing of various sample types, including peripheral blood, amniotic fluid, and bone marrow.

It also offers KayoFlow integrated slide preparation and staining system for pre-analytical slide preparation and staining of chromosome samples; KayoFlow workflow integration systems; and laboratory reagents and consumables.

In addition, the company provides integrated storage, computation, training, and inference localized solutions; and iMed MaaS medical imaging AI platform, a cloud-based service platform. Hangzhou Diagens Biotechnology Co., Ltd. was founded in 2016 and is headquartered in Hangzhou, China.

Stock analysis

Hangzhou Diagens Biotech Co (2526) currently trades at HK$94.75, while our estimate is HK$52.88, 44% below the price, so the stock looks overvalued today.

Show more

Valuation

None of our valuation models currently carries for this company, usually because of losses or heavy investment. The estimate draws on revenue and assets compared with similar companies and is less precise than a model-based fair value.

Scenario range: HK$39.66 (bear) to HK$66.10 (bull), the price of HK$94.75 sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 58/100 (solid quality), in the Healthcare sector.

Expensive Growth: The company is growing, but growth may require heavy reinvestment or weak cash conversion.

Hangzhou Diagens Biotech Co reported revenue of 164M CNY in FY2025 versus 52.8M CNY in FY2023, a compound +76.4%/yr. Reported net income was −67.1M CNY in FY2025.

Key figures

Market cap HK$16.0B (≈ $2.0B) Mid · P/S ratio 87.3 · Net margin −40.8% · Return on equity −39.5% · Return on assets (EBIT) −19.8% (3-year average) · Operating margin −44.3% · Revenue (TTM) 183M CNY · Revenue growth (YoY) +21.0%.

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 12 out of 100 (low confidence).

What moves the price

For context, the median of 10 Healthcare peers we cover trades at 8% fair-value upside, at −44%, 2526 screens richer than that median.

Fair Value

Bear HK$39.66 Fair Value HK$52.88 Bull HK$66.10
Price HK$94.75 · Downside -44.2%
Estimate. None of our valuation models currently carries for this company, usually because of losses or heavy investment. The estimate draws on revenue and assets compared with similar companies and is less precise than a model-based fair value.

Quality Score breakdown

Overall quality 58/100

It rates the business: profits, how they develop, real cash, balance sheet, investing and share count.

Profitability 31
How much profit the company makes from its sales and capital
Quality Growth 60
Are margins and returns getting better?
Cashflow 25
Do the profits arrive as real cash?
Financial strength 80
Debt, balance sheet and risk of trouble
Investment 100
Does it invest with discipline instead of growing at any price?
Low Volatility 0
How calm the share price moves, does not count
Price momentum 0
Price momentum of the last 3 to 12 months, does not count
Near the 52-week high 0
Distance to the 52-week high, does not count
New shares 82
Buys back shares or issues new ones?

Open the full quality analysis →

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 44/100
The company is growing, but growth may require heavy reinvestment or weak cash conversion.
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: only 3 usable fiscal years, at least 4 required
not computed

2526 screens overvalued: fair value 44% below the price. Compare with Abbott Laboratories, →

Compare Hangzhou Diagens Biotech Co with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Medical Devices · 402 stocks

Beats the industry median on 2/7 measures
Overall it trails its industry peers.
Valuation
Quality Score 58 · Above median
Fair Value upside −44.2% · Bottom 25%
Profitability
Return on assets −31.1% · Bottom 25%
Net margin (12 months) −66.4% · Bottom 25%
Operating margin (12 months) −44.3% · Bottom 25%
Growth and dividend
Revenue growth (quarter YoY) 21.0% · Above median

Valuation Multiplesvs Medical Devices median · lower = cheaper

P/S (12 months) 74.22× · Priciest 25%

Strength profile in five axes (Snowflake)

VALUEFUTUREPASTHEALTHDIVIDEND
This stock
VALUEFUTUREPASTHEALTHDIVIDEND
Sector peers
VALUE (fair-value potential)0 · sector 17
FUTURE (revenue growth)100 · sector 44
PAST (return on equity)0 · sector 0
HEALTH (low debt)100 · sector 97
DIVIDEND (yield)0 · sector 34

VALUE 0: the price sits above our fair-value range.

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Medical Devices stocks, each showing price versus our Fair Value estimate.

Stock Price Fair Value vs Fair Value Compare
Shenzhen Mindray Bio-Medical Electronics Co 300760 ¥178.92 ¥202.57 +13% vs 2526
DexCom, Inc DXCM $79.92 $89.18 +12% vs 2526
Stryker Corporation SYK $324.29 $358.30 +10% vs 2526
STERIS plc STE $257.12 $279.53 +9% vs 2526
Boston Scientific Corporation BSX $44.70 $48.42 +8% vs 2526
GE HealthCare Technologies Inc GEHC $83.65 $69.92 −16% vs 2526
Edwards Lifesciences Corporation EW $104.01 $81.94 −21% vs 2526
Abbott Laboratories, ABT $110.46 $75.28 −32% vs 2526
Medtronic plc MDT $101.59 $65.61 −35% vs 2526
Koninklijke Philips N.V PHIA €27.06 €15.23 −44% vs 2526

Explore undervalued stocks

More undervalued Healthcare stocks →

All undervalued stocks TechnologyFinancial ServicesHealthcareConsumer CyclicalConsumer DefensiveCommunication ServicesIndustrialsEnergyBasic MaterialsReal EstateUtilities Deeply Undervalued StocksUndervalued High-Quality StocksUndervalued Blue-Chip StocksUndervalued Small-Cap StocksUndervalued Dividend StocksUndervalued 52-Week Low StocksStocks for 2027: Large Companies Below Fair Value

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

Stock screenerFilter by region, size and sector Compare toolTwo stocks side by side Extrinsic Value Calculator…Free calculator Peter Lynch Fair Value Formula &…Free calculator
Run the numbers yourself: free valuation calculators
DCF CalculatorP/E Ratio CalculatorPEG Ratio CalculatorGraham NumberPeter Lynch FormulaDDM CalculatorIntrinsic ValueIntrinsic vs Extrinsic ValueP/E Ratio by Sector
For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

Hangzhou Diagens Biotech Co: fair value per Fair Value Calculator

Cite: Fair Value Calculator (2026). "Hangzhou Diagens Biotech Co Fair Value". https://www.fairvalue-calculator.com/stock/2526

Frequently asked questions

Is Hangzhou Diagens Biotech Co (2526) overvalued or undervalued?
As of Nov 10, 2026, our estimate of fair value is HK$52.88 versus a price of HK$94.75, about 44% lower (overvalued).
What is the fair value of 2526?
Our estimate for Hangzhou Diagens Biotech Co is HK$52.88 (as of Nov 10, 2026), built from audited fundamentals. The current price: HK$94.75.
What is the quality score of 2526?
Hangzhou Diagens Biotech Co has a Quality Score of 58/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Hangzhou Diagens Biotech Co (2526)?
Our calculated price target is the estimate of HK$52.88 (as of Nov 10, 2026). Cautious scenario HK$39.66, optimistic scenario HK$66.10. It is an estimate from revenue and assets compared with similar companies, because none of our valuation models currently carries, not an analyst target.
What is the Hangzhou Diagens Biotech Co stock forecast for 2026?
Our estimate puts fair value at HK$52.88, about 44% lower versus a price of HK$94.75 (overvalued). Cautious scenario HK$39.66, optimistic scenario HK$66.10. The calculation is refreshed regularly with new filings.
What is the revenue of Hangzhou Diagens Biotech Co (2526)?
Hangzhou Diagens Biotech Co reported trailing-twelve-month revenue of about 183M CNY (latest available figure, as of Nov 10, 2026).
What is the intrinsic value of Hangzhou Diagens Biotech Co (2526)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Hangzhou Diagens Biotech Co it is HK$52.88 per share (as of Nov 10, 2026), against a price of HK$94.75.
Is Hangzhou Diagens Biotech Co stock overvalued or undervalued in 2026?
As of Nov 10, 2026, 2526 trades above its calculated fair value: price HK$94.75, fair value HK$52.88, a gap of about −44% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of 2526?
No. The price is what the market pays today (HK$94.75); the fair value is what the company's own numbers justify (HK$52.88). For Hangzhou Diagens Biotech Co the two are HK$41.87 per share apart. That gap is exactly why we show both numbers side by side.
How much is Hangzhou Diagens Biotech Co worth?
The market values Hangzhou Diagens Biotech Co at about HK$16.0B (market capitalisation, as of Nov 10, 2026). Per share that is HK$94.75; our models calculate a fair value of HK$52.88 per share.
What do the bullish and bearish scenarios say about 2526?
Our models span a range for Hangzhou Diagens Biotech Co: cautious scenario HK$39.66, base HK$52.88, optimistic HK$66.10 per share (as of Nov 10, 2026, price HK$94.75). The range comes from different growth and margin assumptions, not from analyst opinions.
How solid is the balance sheet of Hangzhou Diagens Biotech Co (2526)?
Balance-sheet figures for Hangzhou Diagens Biotech Co (as of Nov 10, 2026): return on equity −39.5%. They feed the Quality Score of 58/100, which measures business quality independently of the share price.
Which stocks are comparable to Hangzhou Diagens Biotech Co?
From the same area (Healthcare) we also value Abbott Laboratories,, Medtronic plc, Stryker Corporation, Boston Scientific Corporation, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Hangzhou Diagens Biotech Co stock attractive at the current price?
The data as of Nov 10, 2026: price HK$94.75, calculated fair value HK$52.88 (−44%), Quality Score 58/100. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
Is it still worth investing in stocks now?
The global stock market currently sits 15.1% above its aggregate fair value. Hangzhou Diagens Biotech Co itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Hangzhou Diagens Biotech Co (2526)?
The closing price on Nov 10, 2026 was HK$94.75. Our estimate is HK$52.88, about 44% lower (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Hangzhou Diagens Biotech Co right now?
The price sits above even our optimistic bull case (HK$66.10). The favourable scenario is already priced in. The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution. Solid but not exceptional quality (58/100) and above fair value, neither a clear bargain nor a standout compounder.

Key figures of Hangzhou Diagens Biotech Co

How large is the market capitalisation of Hangzhou Diagens Biotech Co (2526)?
The market capitalisation of Hangzhou Diagens Biotech Co is HK$16.0B (≈ $2.0B). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Hangzhou Diagens Biotech Co (2526)?
The price-to-sales ratio of Hangzhou Diagens Biotech Co is 87.3 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What is the net margin of Hangzhou Diagens Biotech Co (2526)?
The net margin of Hangzhou Diagens Biotech Co is −40.8% (fiscal year 2025). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Hangzhou Diagens Biotech Co (2526)?
The return on equity (ROE) of Hangzhou Diagens Biotech Co is −39.5% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Hangzhou Diagens Biotech Co (2526)?
On an EBIT basis the return on assets of Hangzhou Diagens Biotech Co is −19.8% (avg 3y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Hangzhou Diagens Biotech Co (2526)?
The operating margin of Hangzhou Diagens Biotech Co is −44.3% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Hangzhou Diagens Biotech Co (2526)?
Revenue at Hangzhou Diagens Biotech Co is growing +21.0% versus a year earlier. How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How much free cash flow does Hangzhou Diagens Biotech Co (2526) generate?
The free cash flow of Hangzhou Diagens Biotech Co is −55.0M CNY (fiscal year 2024). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
Free · no account needed

Watch Hangzhou Diagens Biotech Co in the live analysis

One click puts Hangzhou Diagens Biotech Co on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.